1. Research shows sales growth and R&D spending outperform market over 54 years. 2. Arnott's portfolio strategy could benefit stocks in S&P 500. 3. Top 20 S&P stocks by sales growth included MRNA and NVDA. 4. Sales growth is projected to be modest for many S&P stocks. 5. Moderna experiences sales decline but is expected to recover next year.
The historical performance of the identified strategies suggests positive overall growth. A visible correlation exists between sales performance and stock market returns, which particularly benefits S&P 500 companies poised for sales growth.
Interplay of historical stock performance and sales growth creates significant predictive value for analysts targeting S&P 500 companies. The research has highlighted a solid percentile of outperforming firms, reinforcing investment strategies.
While short-term fluctuations are expected, the consistent application of the sales/per-share growth metric indicates promising long-term performance amid economic cycles, similar to past stock cycles.